199.66
Overview
News
Price History
Option Chain
Financials
Why BDX Down?
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson Co stock is traded at $199.66, with a volume of 1.48M.
It is up +1.54% in the last 24 hours and up +10.14% over the past month.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
See More
Previous Close:
$196.63
Open:
$197.83
24h Volume:
1.48M
Relative Volume:
0.54
Market Cap:
$57.23B
Revenue:
$21.39B
Net Income/Loss:
$1.61B
P/E Ratio:
35.91
EPS:
5.56
Net Cash Flow:
$2.55B
1W Performance:
+1.90%
1M Performance:
+10.14%
6M Performance:
-12.21%
1Y Performance:
-15.15%
Becton Dickinson Co Stock (BDX) Company Profile
Name
Becton Dickinson Co
Sector
Industry
Phone
(201) 847-6800
Address
ONE BECTON DR, FRANKLIN LAKES
Compare BDX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BDX
Becton Dickinson Co
|
199.66 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
![]()
ISRG
Intuitive Surgical Inc
|
476.16 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
![]()
ALC
Alcon Inc
|
82.02 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
![]()
RMD
Resmed Inc
|
293.73 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
![]()
WST
West Pharmaceutical Services Inc
|
247.85 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-22-25 | Downgrade | Citigroup | Buy → Neutral |
May-02-25 | Downgrade | Goldman | Buy → Neutral |
May-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
May-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-01-25 | Downgrade | BofA Securities | Buy → Neutral |
May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
May-01-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
May-30-24 | Initiated | Goldman | Buy |
Jul-24-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-30-23 | Resumed | Morgan Stanley | Overweight |
May-05-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Apr-12-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Jan-03-23 | Upgrade | BofA Securities | Neutral → Buy |
Dec-12-22 | Upgrade | Citigroup | Sell → Neutral |
Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
Jun-24-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-18-22 | Resumed | Raymond James | Mkt Perform |
Mar-02-22 | Resumed | BofA Securities | Neutral |
Dec-08-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
May-25-21 | Initiated | Barclays | Equal Weight |
Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jul-09-20 | Upgrade | Barclays | Equal Weight → Overweight |
Jun-01-20 | Resumed | Goldman | Buy |
Mar-05-20 | Initiated | Citigroup | Neutral |
Feb-07-20 | Downgrade | Cowen | Outperform → Market Perform |
Feb-07-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Feb-07-20 | Downgrade | Raymond James | Strong Buy → Outperform |
Feb-06-20 | Downgrade | Cowen | Outperform → Market Perform |
Jan-08-20 | Downgrade | Barclays | Overweight → Equal Weight |
May-13-19 | Upgrade | Barclays | Equal Weight → Overweight |
Dec-07-18 | Initiated | Deutsche Bank | Buy |
Oct-16-18 | Initiated | Barclays | Equal Weight |
Jun-21-18 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-10-18 | Upgrade | Citigroup | Neutral → Buy |
Jan-19-18 | Resumed | BofA/Merrill | Buy |
Jan-05-18 | Upgrade | Citigroup | Sell → Neutral |
Jan-05-18 | Initiated | KeyBanc Capital Mkts | Overweight |
Jan-03-18 | Initiated | Evercore ISI | Outperform |
Dec-29-17 | Reiterated | Deutsche Bank | Buy |
View All
Becton Dickinson Co Stock (BDX) Latest News
Becton Dickinson and Company stock chart pattern explainedJuly 2025 Pullbacks & Daily Volume Surge Trade Alerts - Newser
Why Becton Dickinson Shares Are Under Scrutiny - TipRanks
Becton, Dickinson and Company (NYSE:BDX) Stock Unloaded Rep. Lisa C. McClain - Defense World
BD PosiFlush™ SafeScrub Study: A Potential Game-Changer for Medical Device Safety - TipRanks
Intravenous Catheters Market Size to Hit USD 16.47 Billion by 2032, at 6.9% CAGR | Report by SNS Insider - GlobeNewswire Inc.
Becton Dickinson and Company stock trend outlook and recovery pathTrade Volume Report & Real-Time Stock Price Movement Reports - Newser
Is Becton Dickinson and Company stock reversal real or fakeRate Cut & Fast Entry High Yield Tips - Newser
Becton, Dickinson and Company Stock: Is Wall Street Bullish or Bearish? - inkl
Becton, Dickinson: Great Time To Buy This Dividend Aristocrat (BDX) - Seeking Alpha
Intraday pattern recognizer results for Becton Dickinson and CompanyWeekly Trend Report & AI Powered Market Entry Ideas - Newser
Does The Market Have A Low Tolerance For Becton, Dickinson and Company's (NYSE:BDX) Mixed Fundamentals? - 富途牛牛
Is Now a Good Time to Reenter Becton Dickinson and Company2025 Breakouts & Breakdowns & Low Drawdown Momentum Trade Ideas - newsimpact.co.kr
Becton Dickinson's (NYSE:BDX) Solid Earnings Have Been Accounted For Conservatively - 富途牛牛
Brandes Investment Partners, LP Makes Significant Addition to Becton Dickinson & Co - Yahoo Finance
Morgan Stanley Forecasts Strong Price Appreciation for Becton, Dickinson and Company (NYSE:BDX) Stock - Defense World
Becton, Dickinson and Company Submits Application to the FDA for a New, At-Home HPV Test - MSN
Becton, Dickinson and Company (NYSE:BDX) Stock Price Expected to Rise, Morgan Stanley Analyst Says - Defense World
Diamond Hill Capital's Strategic Moves: Significant Reduction in Becton Dickinson & Co - Yahoo Finance
Morgan Stanley Reaffirms Their Buy Rating on Becton Dickinson (BDX) - The Globe and Mail
Director’s Bold Move: A Million-Dollar Bet on Becton Dickinson! - TipRanks
Judge OKs Becton Dickinson's $9M Investor Settlement - Law360
Becton Dickinson price target raised to $197 from $196 at Morgan Stanley - TipRanks
Morgan Stanley Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Raises Target Price to $197 - 富途牛牛
Becton, Dickinson rises as strong Q3 results lead to guidance raise - MSN
4 Overlooked Dividend Aristocrat Stocks with Up To 60%+ Growth Potential - 24/7 Wall St.
BD Careers | Jobs at BD | We are the Makers of Possible - Becton Dickinson
Earnings Beat: Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
Piper Sandler Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Raises Target Price to $200 - 富途牛牛
Becton, Dickinson and Company (NYSE:BDX) Raised to Buy at Wall Street Zen - Defense World
J.P. Morgan Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Raises Target Price to $190 - 富途牛牛
Director Makes Significant Move with Becton Dickinson Stock! - TipRanks
A Quick Look at Today's Ratings for Becton Dickinson & Co(BDX.US), With a Forecast Between $183 to $200 - 富途牛牛
Becton Dickinson: Wells Fargo maintains Equal-Weight, raises PT to $184 from $172. - AInvest
Becton, Dickinson and Company (NYSE:BDX) Q3 2025 Earnings Call Transcript - Insider Monkey
Becton Dickinson price target raised to $200 from $185 at Piper Sandler - TipRanks
Piper Sandler raises Becton Dickinson stock price target to $200 on earnings beat - Investing.com
William Blair Maintains Becton Dickinson & Co(BDX.US) With Hold Rating - 富途牛牛
BD revenue up 10.4% to USD 5.5 billion in Q3 2025 - Medical Buyer
Becton Dickinson & Co (BDX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Becton Dickinson Reports Strong Q3 2025 Results - TipRanks
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MSN
Becton, Dickinson and Co’s Optimistic Earnings Call - TipRanks
Becton Dickinson: Fiscal Q3 Earnings Snapshot - Chron
Becton Dickinson and Co reports results for the quarter ended June 30Earnings Summary - TradingView
Becton Dickinson Q3 Beats Estimates On Medical Device Boom - inkl
Earnings call transcript: Becton Dickinson Q3 2025 earnings beat forecasts, stock surges - Investing.com
Becton Dickinson Earnings: Return to Organic Growth; Raised EPS Guidance; Shares Remain Undervalued - Morningstar
Becton, Dickinson stock rises on Q3 beat (BDX:NYSE) - Seeking Alpha
Becton, Dickinson and Company 2025 Q3ResultsEarnings Call Presentation (NYSE:BDX) - Seeking Alpha
Becton, Dickinson Boosts FY25 Adj. EPS OutlookUpdate - Nasdaq
Becton Dickinson Q3 FY25 presentation: Organic growth accelerates, guidance raised - Investing.com India
Becton Dickinson Co Stock (BDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Becton Dickinson Co Stock (BDX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Fraser Claire | Director |
Aug 08 '25 |
Sale |
192.30 |
863 |
165,955 |
23,143 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):